Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002787 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
A Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00002787 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. The registered enrollment target is 22 participants.
The verdict
NCT00002787, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL autologous immunoglobulin idiotype-KLH conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 1996-03 |
| Phase | Phase 1 |
Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002787
The ClinicalTrials.gov registry entry for NCT00002787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00002787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002787 about?
NCT00002787 is a clinical study titled "Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation". The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
What is the current status of trial NCT00002787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 1996-03.
What interventions are being tested in trial NCT00002787?
The interventions under investigation include: laboratory biomarker analysis (OTHER), aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), autologous immunoglobulin idiotype-KLH conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002787?
This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.